Crestchem Q4 profit rises 81%, recommends ₹1.50 dividend
Crestchem Limited reported a standalone net profit of ₹110.38 lakh for Q4FY26, up from ₹61.04 lakh in the prior year, with revenue rising to ₹1,022.53 lakh. The board recommended a final dividend of ₹1.50 per share and approved the reappointment of three directors for five years. The company also incorporated a subsidiary, Oleo Biosciences Private Limited, during the year.
*this image is generated using AI for illustrative purposes only.
Crestchem Limited reported a standalone net profit of ₹110.38 lakh for the quarter ended March 31, 2026, rising from ₹61.04 lakh in the corresponding period of the previous year. Revenue from operations for the quarter stood at ₹1,022.53 lakh, compared to ₹723.20 lakh in Q4FY25. For the full financial year ended March 31, 2026, the company recorded a net profit of ₹271.35 lakh on revenue of ₹2,960.74 lakh.
The board of directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Additionally, the board recommended a final dividend of ₹1.50 per equity share, or 15%, for the financial year 2025-26. This dividend is subject to the approval of shareholders at the upcoming 34th Annual General Meeting.
During the financial year, the company incorporated a subsidiary, Oleo Biosciences Private Limited, in Bangalore, Karnataka, on March 31, 2026. Crestchem holds a 75% stake in the new entity. The subsidiary has not commenced commercial operations, and no significant financial transactions were carried out during the year, except for the recognition of subscription money.
The board approved the reappointment of three key managerial personnel for a five-year term. Mr. Dipak Narendraprasad Patel, Mrs. Parul Dipak Patel, and Mrs. Tansi Nimit Patel were reappointed for periods ranging from April 1, 2026, to October 1, 2031. Furthermore, the board authorized an investment of up to ₹2.25 crore in the new subsidiary through loans, inter-corporate deposits, or equity share capital.
The financial results were reviewed by the audit committee and subsequently taken on record by the board on May 29, 2026. Samir M. Shah & Associates, Chartered Accountants, audited the standalone and consolidated financial results.
Standalone Financial Results
| Particulars | Quarter ended Mar 31, 2026 (₹ in Lacs) | Quarter ended Mar 31, 2025 (₹ in Lacs) | Year ended Mar 31, 2026 (₹ in Lacs) | Year ended Mar 31, 2025 (₹ in Lacs) |
|---|---|---|---|---|
| Revenue from operations | 1,022.53 | 723.20 | 2,960.74 | 2,507.72 |
| Total Income | 1,042.91 | 737.27 | 3,026.62 | 2,551.59 |
| Total Expenses | 885.16 | 664.67 | 2,650.88 | 2,185.91 |
| Profit before tax | 157.75 | 72.59 | 375.75 | 365.68 |
| Net profit | 110.38 | 61.04 | 271.35 | 272.65 |
| Earnings per share (Basic) | 3.67 | 2.03 | 9.03 | 9.09 |
Historical Stock Returns for Crestchem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.86% | -5.06% | +9.16% | +18.36% | -18.98% | +249.94% |
What strategic advantages does the new subsidiary, Oleo Biosciences, offer to Crestchem's existing business portfolio?
When is the expected timeline for Oleo Biosciences to commence commercial operations and contribute to revenue?
How does Crestchem plan to utilize the authorized ₹2.25 crore investment to drive growth in the new subsidiary?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
